Mouse anti-Human Myeloperoxidase-C2 (FITC) and CD3 (PE) Antibody
COMBI IC Reagent: Mouse anti Myeloperoxidase-C2 (FITC) and Mouse anti CD3 (PE)
Reactivity
Human
Applications
Flow Cytometry, Functional Assay
Synonyms
Myeloperoxidase-C2 (FITC) and CD3 (PE); COMBI IC Reagent: Mouse anti Myeloperoxidase-C2 (FITC) and Mouse anti CD3 (PE); anti-Myeloperoxidase-C2 (FITC) and CD3 (PE) antibody
Host
Mouse
Reactivity
Human
Isotype
IgG1
Clone Number
8E6; UCHT1
Specificity
Antibody MPO-C2 (clone 8E2) reacts with human myeloperoxidase (MPO) expressed by normal and malignant myelomonocytic cells.
The CD3 mAb (clone UCHT1) recognizes cytoplasmatic CD3 epsilon in precursor T-cells and cytoplasmic and surface CD3
epsilon in mature T-lymphocytes.
In this COMBI-IC Reagent antibody 8E6 is conjugated to FITC, antibody UCHT1 is conjugated to Phycoeythrin (PE).
The CD3 mAb (clone UCHT1) recognizes cytoplasmatic CD3 epsilon in precursor T-cells and cytoplasmic and surface CD3
epsilon in mature T-lymphocytes.
In this COMBI-IC Reagent antibody 8E6 is conjugated to FITC, antibody UCHT1 is conjugated to Phycoeythrin (PE).
Form/Format
PBS pH 7.2, 1 mg/ml BSA, 0.0.5% NaN3
Applicable Applications for anti-Myeloperoxidase-C2 (FITC) and CD3 (PE) antibody
Flow Cytometry (FC/FACS)
Application Notes
Permeabilization and Staining Procedure
- In combination with our Permeabilization Kit FIX&PERM intracellular MPO-C2 and CD3 can be easily stained in cell suspensions
- For each sample to be analyzed add 50 ul of whole blood, bone marrow or mononuclear cell suspension in a 5 ml tube
- Add 100 ul of Reagent A (Fixation Medium, stored and used at room temperature)
- Incubate for 15 minutes at room temperature
- Add 5 ml phosphate buffered saline and centrifuge cells for 5 minutes at 300 g
- Remove supernatant and add to cell pellet 100 ul Reagent B (Permeabilization Medium) and 20 ul of the MPO-C2/CD3 COMBI-IC monoclonal antibody conjugate
- Vortex at low speed for 1-2 seconds
- Incubate for 15 minutes at room temperature
- Wash cells with phosphate buffered saline as described above
-Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1.0 % formaldehyde and store them at 2-8 degree C in the dark. Analyze fixed
cells within 24 hours
- In combination with our Permeabilization Kit FIX&PERM intracellular MPO-C2 and CD3 can be easily stained in cell suspensions
- For each sample to be analyzed add 50 ul of whole blood, bone marrow or mononuclear cell suspension in a 5 ml tube
- Add 100 ul of Reagent A (Fixation Medium, stored and used at room temperature)
- Incubate for 15 minutes at room temperature
- Add 5 ml phosphate buffered saline and centrifuge cells for 5 minutes at 300 g
- Remove supernatant and add to cell pellet 100 ul Reagent B (Permeabilization Medium) and 20 ul of the MPO-C2/CD3 COMBI-IC monoclonal antibody conjugate
- Vortex at low speed for 1-2 seconds
- Incubate for 15 minutes at room temperature
- Wash cells with phosphate buffered saline as described above
-Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1.0 % formaldehyde and store them at 2-8 degree C in the dark. Analyze fixed
cells within 24 hours
CE Mark
CE
Conjugation
FITC and PE
Preparation and Storage
Monoclonal antibody reagents contain optimal concentrations of affinity-purified antibody. For stability reasons this monoclonal antibody solution contains sodium azide. These reagents should be stored at 2-8 degree C (DO NOT FREEZE!) and protected from prolonged exposure to light. Stability of the reagent: Please refer to the expiry date printed onto the vial. The use of the reagent after the expiration date is not recommended.
Related Product Information for anti-Myeloperoxidase-C2 (FITC) and CD3 (PE) antibody
Myeloperoxidase (MPO) is a glycoprotein present in the azurophil (primary) granules of myeloid cells, which appears in the myeloblast stage of myeloid cell differentiation. MPO is he most common functional protein of myeloid cells and is involved in the inflammatory response. It helps to kill microbes by breaking down peroxide in the presence of halide ions, contributing to the bactericidal function of granulocytes. The primary translation product of MPO undergoes glycosylation with production of the 89 kDa heme-free apopro-MPO form followed by incorporation of heme and conversion into the enzymatically active pro-MPO form. Subsequently, pro-MPO becomes targeted to azurophil granules where final processing occurs to produce mature dimeric MPO consisting of the 59-64 kDa MPO a-chain and the 14 kDa MPO b-chain.
Precursor T-cells are surface CD3 negative but positive for cytoplasmatic CD3. All mature T cells are both cytoplasmic and surface CD3 positive. The combined staining for MPO and CD3 allows the distinction of cells derived form the myeloid lineage that are generally MPO positive, from immature and mature T lymphocytes during normal and malignant hematopoiesis.
The MPO-C2/CD3 COMBI-IC reagent permits the identification and enumeration of normal and malignant human blood and bone marrow cells using flow cytometry. Results must be put within the context of other tests as well as the clinical history of the patient by a certified professional before final interpretation. Analysis performed with this antibody should be paralleled by positive and negative controls.
Precursor T-cells are surface CD3 negative but positive for cytoplasmatic CD3. All mature T cells are both cytoplasmic and surface CD3 positive. The combined staining for MPO and CD3 allows the distinction of cells derived form the myeloid lineage that are generally MPO positive, from immature and mature T lymphocytes during normal and malignant hematopoiesis.
The MPO-C2/CD3 COMBI-IC reagent permits the identification and enumeration of normal and malignant human blood and bone marrow cells using flow cytometry. Results must be put within the context of other tests as well as the clinical history of the patient by a certified professional before final interpretation. Analysis performed with this antibody should be paralleled by positive and negative controls.
References
Andersson, E., Hellman, L., Gullberg, U. & Olsson, I. (1998) J Biol Chem 273, 4747-53.
Beverley, P. C., Linch, D. & Callard, R. E. (1981) Haematol Blood Transfus 26, 309-13
Braylan, R. C., Orfao, A., Borowitz, M. J. & Davis, B. H. (2001) Cytometry 46, 23-7.
Campana, D., Thompson, J. S., Amlot, P., Brown, S. & Janossy, G. (1987) J Immunol 138, 648-55.
Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21.
Cowland, J. B. & Borregaard, N. (1999) J Leukoc Biol 66, 989-95.
Cramer, E., Pryzwansky, K. B., Villeval, J. L., Testa, U. & Breton-Gorius, J. (1985) Blood 65, 423-32
Groeneveld, K., te Marvelde, J. G., van den Beemd, M. W., Hooijkaas, H. & van Dongen, J. J. (1996) Leukemia 10, 1383-9.
Imamura, N. (1998) Am J Hematol 58, 241-3.
Janossy, G., Coustan-Smith, E. & Campana, D. (1989) Leukemia 3, 170-81.
Knapp, W., Majdic, O. & Strobl, H. (1993) Recent Results Cancer Res 131, 31-40.
Koeffler, H. P., Ranyard, J. & Pertcheck, M. (1985) Blood 65, 484-91.
Konikova, E., Glasova, M., Kusenda, J. & Babusikova, O. (1998) Neoplasma 45, 282-91.
Murao, S., Stevens, F. J., Ito, A. & Huberman, E. (1988) Proc Natl Acad Sci U S A 85, 1232-6.
Nakase, K., Sartor, M. & Bradstock (1998) Cytometry 34, 198-202.
Nauseef, W. M. (1990) Hematol Pathol 4, 165-78.
Nauseef, W. M., Olsson, I. & Arnljots, K. (1988) Eur J Haematol 40, 97-110.
Paietta, E. (2003) Best Pract Res Clin Haematol 16, 671-83.
Rani, S., De Oliveira, M. S. & Catovsky, D. (1988) Hematol Pathol 2, 73-8.
Srivastava, C. H., Rado, T. A., Bauerle, D. & Broxmeyer, H. E. (1991) J Immunol 146, 1014-9
Strobl, H. & Knapp, W. (2004) J Biol Regul Homeost Agents 18, 335-9.
Strobl, H., Takimoto, M., Majdic, O., Fritsch, G., Scheinecker, C., Hocker, P. & Knapp, W. (1993) Blood 82, 2069-78.
Tsuruta, T., Tani, K., Hoshika, A. & Asano, S. (1999) Leuk Lymphoma 32, 257-67.
Vainchenker, W., Villeval, J. L., Tabilio, A., Matamis, H., Karianakis, G., Guichard, J., Henri, A., Vernant, J. P., Rochant, H. & Breton-Gorius, J. (1988) Leukemia 2, 274-81.
van der Schoot, C. E., Daams, G. M., Pinkster, J., Vet, R. & von dem Borne, A. E. (1990) Br J Haematol 74, 173-8.
Vainchenker, W., Villeval, J. L., Tabilio, A., Matamis, H., Karianakis, G., Guichard, J., Henri, A., Vernant, J. P., Rochant, H. & Breton-Gorius, J. (1988) Leukemia 2, 274-81.
van der Schoot, C. E., Daams, G. M., Pinkster, J., Vet, R. & von dem Borne, A. E. (1990) Br J Haematol 74, 173-8.
van der Schoot, C. E., von dem Borne, A. E. & Tetteroo, P. A. (1987) Acta Haematol 78 Suppl 1, 32-40.
Beverley, P. C., Linch, D. & Callard, R. E. (1981) Haematol Blood Transfus 26, 309-13
Braylan, R. C., Orfao, A., Borowitz, M. J. & Davis, B. H. (2001) Cytometry 46, 23-7.
Campana, D., Thompson, J. S., Amlot, P., Brown, S. & Janossy, G. (1987) J Immunol 138, 648-55.
Catovsky, D., Matutes, E., Buccheri, V., Shetty, V., Hanslip, J., Yoshida, N. & Morilla, R. (1991) Ann Hematol 62, 16-21.
Cowland, J. B. & Borregaard, N. (1999) J Leukoc Biol 66, 989-95.
Cramer, E., Pryzwansky, K. B., Villeval, J. L., Testa, U. & Breton-Gorius, J. (1985) Blood 65, 423-32
Groeneveld, K., te Marvelde, J. G., van den Beemd, M. W., Hooijkaas, H. & van Dongen, J. J. (1996) Leukemia 10, 1383-9.
Imamura, N. (1998) Am J Hematol 58, 241-3.
Janossy, G., Coustan-Smith, E. & Campana, D. (1989) Leukemia 3, 170-81.
Knapp, W., Majdic, O. & Strobl, H. (1993) Recent Results Cancer Res 131, 31-40.
Koeffler, H. P., Ranyard, J. & Pertcheck, M. (1985) Blood 65, 484-91.
Konikova, E., Glasova, M., Kusenda, J. & Babusikova, O. (1998) Neoplasma 45, 282-91.
Murao, S., Stevens, F. J., Ito, A. & Huberman, E. (1988) Proc Natl Acad Sci U S A 85, 1232-6.
Nakase, K., Sartor, M. & Bradstock (1998) Cytometry 34, 198-202.
Nauseef, W. M. (1990) Hematol Pathol 4, 165-78.
Nauseef, W. M., Olsson, I. & Arnljots, K. (1988) Eur J Haematol 40, 97-110.
Paietta, E. (2003) Best Pract Res Clin Haematol 16, 671-83.
Rani, S., De Oliveira, M. S. & Catovsky, D. (1988) Hematol Pathol 2, 73-8.
Srivastava, C. H., Rado, T. A., Bauerle, D. & Broxmeyer, H. E. (1991) J Immunol 146, 1014-9
Strobl, H. & Knapp, W. (2004) J Biol Regul Homeost Agents 18, 335-9.
Strobl, H., Takimoto, M., Majdic, O., Fritsch, G., Scheinecker, C., Hocker, P. & Knapp, W. (1993) Blood 82, 2069-78.
Tsuruta, T., Tani, K., Hoshika, A. & Asano, S. (1999) Leuk Lymphoma 32, 257-67.
Vainchenker, W., Villeval, J. L., Tabilio, A., Matamis, H., Karianakis, G., Guichard, J., Henri, A., Vernant, J. P., Rochant, H. & Breton-Gorius, J. (1988) Leukemia 2, 274-81.
van der Schoot, C. E., Daams, G. M., Pinkster, J., Vet, R. & von dem Borne, A. E. (1990) Br J Haematol 74, 173-8.
Vainchenker, W., Villeval, J. L., Tabilio, A., Matamis, H., Karianakis, G., Guichard, J., Henri, A., Vernant, J. P., Rochant, H. & Breton-Gorius, J. (1988) Leukemia 2, 274-81.
van der Schoot, C. E., Daams, G. M., Pinkster, J., Vet, R. & von dem Borne, A. E. (1990) Br J Haematol 74, 173-8.
van der Schoot, C. E., von dem Borne, A. E. & Tetteroo, P. A. (1987) Acta Haematol 78 Suppl 1, 32-40.
Similar Products
Product Notes
The Myeloperoxidase-C2 (FITC) and CD3 (PE) (Catalog #AAA570355) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The COMBI IC Reagent: Mouse anti Myeloperoxidase-C2 (FITC) and Mouse anti CD3 (PE) reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's Myeloperoxidase-C2 (FITC) and CD3 (PE) can be used in a range of immunoassay formats including, but not limited to, Flow Cytometry (FC/FACS). Permeabilization and Staining Procedure - In combination with our Permeabilization Kit FIX&PERM intracellular MPO-C2 and CD3 can be easily stained in cell suspensions - For each sample to be analyzed add 50 ul of whole blood, bone marrow or mononuclear cell suspension in a 5 ml tube - Add 100 ul of Reagent A (Fixation Medium, stored and used at room temperature) - Incubate for 15 minutes at room temperature - Add 5 ml phosphate buffered saline and centrifuge cells for 5 minutes at 300 g - Remove supernatant and add to cell pellet 100 ul Reagent B (Permeabilization Medium) and 20 ul of the MPO-C2/CD3 COMBI-IC monoclonal antibody conjugate - Vortex at low speed for 1-2 seconds - Incubate for 15 minutes at room temperature - Wash cells with phosphate buffered saline as described above -Remove supernatant and resuspend cells in sheath fluid for immediate analysis or resuspend cells in 0.5 ml 1.0 % formaldehyde and store them at 2-8 degree C in the dark. Analyze fixed cells within 24 hours. Researchers should empirically determine the suitability of the Myeloperoxidase-C2 (FITC) and CD3 (PE) for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "Myeloperoxidase-C2 (FITC) and CD3 (PE), Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
